Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.33 |
| ▸ | GLP1R | P43220 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16206096 | 0.92 | GABRA5 (0.35) | KMOHTR7GRIN2BGRIN1 | |
| SCHEMBL17614555 | 0.92 | FFAR4 (0.35) | FFAR4GLP1RCYP11B1CYP11B2HTR7 | |
| SCHEMBL16206032 | 0.91 | ALDH1A1 (0.40) | FFAR4GLP1RNR4A2DHODH | |
| SCHEMBL16205991 | 0.90 | GABRA5 (0.35) | CYP11B1CYP11B2HTR7 | |
| SCHEMBL17614527 | 0.88 | GRM2 (0.36) | KMOHTR7 | |
| SCHEMBL17614537 | 0.88 | HTR7 (0.33) | CYP11B1CYP11B2HTR7 | |
| SCHEMBL16206095 | 0.88 | HTR7 (0.34) | CYP11B1CYP11B2HTR7 | |
| SCHEMBL16205996 | 0.86 | GABRA5 (0.36) | HTR7 | |
| SCHEMBL16206004 | 0.86 | HTR7 (0.33) | HSD11B1CYP11B1CYP11B2HTR7 | |
| SCHEMBL16206109 | 0.85 | SMN1; SMN2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9867372-B2 | Tetrazolinone compound and use of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-01-16 | — | — | US | disclosed |
| US-20160081339-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160081339-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | MT-CO1, SOD1, MT-CO2 | KMO 1060/4885HSD11B1 903/4885FFAR4 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.